
About this episode
I sit down with Dr Asaf Maoz, Medical Oncologist at Dana Farber Cancer Institute, who I recently saw at the LynkedIn and Scientific Symposium. We discussed what brought Dr Maoz to this point, discussing immunology, T-cells, receptors and targets. Dr Maoz confirmed that not all Lynch cancers are MSI-H. This year, for the 5 year anniversary of the patient LynkedIn conference, they had the scientific symposium the day before. Dr Michael Foote from MSK presented some data on cancer risk after immunotherapy. I appreciate the debates and conversations that take place at the symposiums, and how data will continue to drive innovation, but like anything, until you generate the data you can't hypothesize and stratify. Of course we ventured into the cancer vaccine space and the unique molecular features of Lynch Syndrome and the potential to prevent cancer in the future. Takeaway is to keep up with screening regardless. We also discussed language barriers to healthcare overall, not just Lynch Syndrome, including how AI is being looked at in order to potentially find tidbits that are missed.
Get every episode summarized
Each time AliveandKick'n the podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from AliveandKick'n the podcast

AliveAndKickn Podcast - Hanna Lombardi
AliveandKick'n the podcast

AliveAndKickn Podcast - Stef Alastre
AliveandKick'n the podcast

AliveAndKickn Podcast - Dr Mev Dominguez
AliveandKick'n the podcast

AliveAndKickn Podcast - Laura Schneebaum
AliveandKick'n the podcast